NEW YORK, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against RxSight, Inc. (NASDAQ: RXST) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in RxSight, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases-investigations/rxsight-inc-class-action-lawsuit. Investors have until September 22, 2025, to ask the Court to ...

MINNEAPOLIS, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on fluid management, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for a new size of its Dual Lumen Extended Length Catheter (dELC). Advancing a broader fluid management platform: This clearance supports Nuwellis’ multi-year plan to build a comprehensive fluid management platform—combining therapy delivery, dedicated venous access, and practical implem ...

Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development, and commercialization of innovative solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing advanced adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The iLet Bionic Pancreas is the first FDA-cleared insulin delivery device that autonomously determines every insulin dose and offers the potential to substantially im ...

Fort Mill, S.C., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market today announced that the LockeT Compare Study has enrolled its first three patients. The LockeT Compare Study is a single center, physician-initiated study that will enroll up to 100 patients and evaluate the safety profile of the LockeT suture retention device compared to interna ...

This investment marks BrainsWay’s entrance into the market for mental health therapies that can be administered outside of a clinic, including at home Neurolief’s breakthrough Proliv™Rx device is pending Premarket Approval from the U.S. FDA, and if granted, will become the first FDA-cleared medical device for MDD treatment that can be delivered outside of the clinic BURLINGTON, Mass. and JERUSALEM, Aug. 21, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a glob ...

Financial Data and Key Metrics Changes - Operating revenues surpassed $2,000,000,000 for the first time, reaching $2,020,000,000, which is a 14% increase in constant currency [34][13] - Net profit after tax was $377,200,000, reflecting a 30% increase in constant currency compared to the previous year [34][13] - Gross margin improved to 62.9%, an increase of 1.3% in constant currency [36] Business Line Data and Key Metrics Changes - Hospital business revenue was $1,280,000,000, up 16% in constant currency [34] - Home care business revenue reached $739,900,000, an 11% increase in constant currency [34] Market Data and Key Metrics Changes - The company’s products were used to treat 22 million patients in FY 2025, indicating strong market demand [30] - The manufacturing facility in China became fully operational, contributing to sales [31] Company Strategy and Development Direction - The company focuses on long-term planning, with a perspective extending beyond 15 years, guiding R&D and infrastructure investments [6][8] - Infrastructure investments include the construction of a fifth building at the East Tamaki campus and securing land for a second campus in New Zealand [8][7] - The company aims to double its revenue every five to six years sustainably [60] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the impact of global geopolitics and tariffs but emphasized a long-term strategy to mitigate cost increases through continuous improvements [9][12] - The outlook for FY 2026 anticipates revenue between $2,150,000,000 and $2,250,000,000, with net profit after tax expected to be between $390,000,000 and $440,000,000 [56] Other Important Information - The company is committed to maintaining a prudent balance sheet while investing in R&D and global sales [14] - The board approved a 2% increase in dividends, totaling $0.0425 per share, representing a payout ratio of about 66% [13][14] Q&A Session Summary Question: Why hasn't the company conducted a major investor day like Xero? - The company complies with New Zealand regulations and believes its disclosures are adequate, thus not planning to adopt the Australian remuneration report [66] Question: What are the expectations for FY 2026 underlying profit? - Management referred to the outlook provided earlier, indicating a long-term growth trajectory despite fluctuations during the COVID period [68] Question: How many shareholders voted in favor of the CEO's reelection? - The number of votes will be disclosed at the end of the meeting, but the focus will be on the number of votes rather than individual shareholders [84]

The shares benefited from a clutch of analyst price target hikes. A clutch of post-earnings price target increases by analysts helped raise Medtronic's (MDT 3.59%) stock at a healthy rate on Wednesday. The sturdy medical device specialist's shares rose by almost 4% on the day as a consequence, a rate that looked especially good next to the S&P 500's (^GSPC -0.24%) 0.2% drop. The market, which collectively loves a crushing beat on analyst estimates, basically shrugged at this. Many investors traded out of Me ...

SAN DIEGO, Aug. 20, 2025 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired RxSight, Inc. (NASDAQ: RXST) securities between November 7, 2024 and July 8, 2025. RxSight is a commercial-stage medical technology company, engaged in the research and development, manufacture, and sale of light adjustable intraocular lenses ("LAL") used in cataract surgery in the United States. The Company's primary product is the RxSight system ...

Core Insights - Medtronic Plc reported second-quarter earnings and announced key board appointments following Elliott Investment Management becoming the largest shareholder [1] - The company introduced a new Growth Committee to oversee strategic M&A, R&D investments, and potential divestitures, including the planned separation of its Diabetes business [1] Financial Performance - Medtronic's first-quarter 2026 sales reached $8.58 billion, exceeding the consensus estimate of $8.38 billion, representing an 8.4% year-over-year increase with organic growth of 4.8% [2] - Adjusted earnings per share were $1.26, surpassing expectations of $1.23 [2] Sales Guidance - The company raised its sales guidance for fiscal 2026 from a range of $35.15 billion to $35.25 billion to a new range of $35.72 billion to $35.82 billion, compared to the consensus of $35.32 billion [3] Analyst Reactions - Needham's analyst Mike Matson believes Medtronic is in the early stages of a strong product cycle and expects Elliott's involvement to enhance shareholder value, but maintains a Hold rating until organic growth shows meaningful acceleration beyond 5% [4] - Matson raised fiscal 2026 and 2027 revenue estimates to $35.81 billion from $35.29 billion and to $37.69 billion from $36.96 billion, respectively [5] - Bernstein maintains an Outperform rating on Medtronic, raising the price forecast from $97 to $98, while Baird maintains a Neutral rating, increasing the price forecast from $94 to $96 [6] Stock Performance - Medtronic's stock increased by 4.07%, reaching $93.56 at the last check on Wednesday [6]

Key Takeaways DXCM posts strong growth, expanding access and raising FY25 revenue outlook.DXCM momentum led by type 2 wins, Stelo adoption and 15-day G7 launch.DXCM focuses on global growth, AI integration and margin recovery.DexCom, Inc. (DXCM) reported second-quarter 2025 results that highlighted robust top-line growth, continued progress in expanding access and meaningful product innovation. Revenues grew 15% year over year to $1.16 billion, with broad-based contributions from both the U.S. and internati ...